Inventiva Appoints new CFO, CLO and CPO
Inventiva announced 3 new members of its leadership team: Axel-Sven Malkomes as Chief Financial Officer, Susan Coles as Chief Legal Officer, and Pamela Herbster as Chief People Officer. Malkomes has >30 years of experience in life sciences and healthcare including recently co-leading an acquisition during his role as CFO of Cardior. Both Coles and Herbster also have significant industry experience, where they have been involved in business development agreements through their previous roles e.g. at Vivet Therapeutics, and EMD Serono/Merck KGaA, respectively. The deal making experience that the new hires bring will be key for Inventiva as the company approaches topline phase 3 data for lanifibranor in MASH, which if positive, could attract significant pharma interest. € 7 TP and Buy maintained.Inventiva is a clinical stage biotechnology research company delivering therapies in the areas of oncology, fibrosis and rare diseases. The most advanced clinical programs (IVA337 for systemic sclerosis in Non-Alcoholic Steato-Hepatitis and IVA336 for Maroteaux-Lamy syndrome-MPS VI) have demonstrated efficacy in relevant in vivo and in vitro models as well as safety in phase I and phase II clinical trials. Using its in-house drug discovery platform, which covers target validation, screening, chemistry, ADME and pharmacology, Co. is developing an internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets and nuclear receptors.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.